These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 11371107)

  • 1. Triple marker screening for fetal chromosomal abnormalities in Korean women of advanced maternal age.
    Kim SK; Bai SW; Chung JE; Jung YN; Park KH; Cho DJ; Kim JW; Yang YH; Song CH
    Yonsei Med J; 2001 Apr; 42(2):199-203. PubMed ID: 11371107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
    McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
    J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing the need for amniocentesis in women 35 years of age or older with serum markers for screening.
    Haddow JE; Palomaki GE; Knight GJ; Cunningham GC; Lustig LS; Boyd PA
    N Engl J Med; 1994 Apr; 330(16):1114-8. PubMed ID: 7510852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience on triple markers serum screening for Down's syndrome fetus in Hat Yai, Regional Hospital.
    Lamlertkittikul S; Chandeying V
    J Med Assoc Thai; 2007 Oct; 90(10):1970-6. PubMed ID: 18041410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective evaluation of maternal serum screening for the detection of fetal aneuploidy.
    Suzumori K; Tanemura M; Murakami I; Okada S; Natori M; Tanaka M; Takagi T; Sato A
    Prenat Diagn; 1997 Sep; 17(9):861-6. PubMed ID: 9316131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prenatal maternal blood screening for the detection of fetal chromosomal abnormalities: clinical importance of the rate of false positives].
    Alvarez-Nava F; Soto M; Padrón T; Morales A; Villalobos D; Rojas de Atencio A; Prieto M; Martínez MC
    Invest Clin; 2003 Sep; 44(3):195-207. PubMed ID: 14552058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Noninvasive serum test for prenatal detection of Down syndrome, other chromosome abnormalities and open neural tube defects--a prospective study].
    Zwahr C; Voss P; Kistner G
    Geburtshilfe Frauenheilkd; 1994 Jun; 54(6):355-61. PubMed ID: 7522195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The advantages of using triple-marker screening for chromosomal abnormalities.
    Kellner LH; Weiss RR; Weiner Z; Neuer M; Martin GM; Schulman H; Lipper S
    Am J Obstet Gynecol; 1995 Mar; 172(3):831-6. PubMed ID: 7534448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maternal serum screening of fetal chromosomal abnormalities by AFP, UE3, hCG and free-beta hCG. Prospective and retrospective results.
    Valerio D; Aiello R; Altieri V; Fagnoni P
    Minerva Ginecol; 1996 May; 48(5):169-73. PubMed ID: 8783867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of Down's syndrome screening methods using maternal serum biochemistry in the second trimester pregnancy].
    Yu DY; Fu P; Zhang ZH; Wang F; Han MY; Ren HY; Zhao W; Zhang K; Li S; Jiang N
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Jun; 28(3):332-5. PubMed ID: 21644235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trimester screening program for Down syndrome.
    Mooney RA; Peterson CJ; French CA; Saller DN; Arvan DA
    Obstet Gynecol; 1994 Aug; 84(2):298-303. PubMed ID: 7518896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-trimester repeated measures testing for Down's syndrome screening: an assessment.
    Wright D; Bradbury I; Malone F; D'Alton M; Summers A; Huang T; Ball S; Baker A; Nix B; Aitken D; Crossley J; Cuckle H; Spencer K
    Health Technol Assess; 2010 Jul; 14(33):1-80. PubMed ID: 20624355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Value of detection of cell-free fetal DNA in maternal plasma in the prenatal diagnosis of chromosomal abnormalities].
    Wang SJ; Gao ZY; Lu YP; Li YL; You YQ; Zhang LW; Wang LX; Xu H
    Zhonghua Fu Chan Ke Za Zhi; 2012 Nov; 47(11):808-12. PubMed ID: 23302119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for fetal Down's syndrome in pregnancy by measuring maternal serum alpha-fetoprotein levels.
    DiMaio MS; Baumgarten A; Greenstein RM; Saal HM; Mahoney MJ
    N Engl J Med; 1987 Aug; 317(6):342-6. PubMed ID: 2439909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-trimester maternal serum alpha-fetoprotein and human chorionic gonadotrophin screening for Down's syndrome in Hong Kong.
    Lam YH; Ghosh A; Tang MH; Tang LC; Lee CP; Sin SY; Ho PK
    Prenat Diagn; 1998 Jun; 18(6):585-89. PubMed ID: 9664604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Second trimester maternal serum screening for Down's syndrome in women of advanced maternal age: a multi-center prospective study].
    Qi QW; Jiang YL; Liu JT; Bian XM; Li Y; Lü SM; Zhu BS; Wang H; Xu ZF; Pan XY; Cai Y
    Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):737-41. PubMed ID: 19087538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maternal serum screening for birth defects: results of a Connecticut regional program.
    Benn PA; Horne D; Craffey A; Collins R; Ramsdell L; Greenstein R
    Conn Med; 1996 Jun; 60(6):323-7. PubMed ID: 8706425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy.
    Aitken DA; Wallace EM; Crossley JA; Swanston IA; van Pareren Y; van Maarle M; Groome NP; Macri JN; Connor JM
    N Engl J Med; 1996 May; 334(19):1231-6. PubMed ID: 8606718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prenatal screening for Down's syndrome using inhibin-A as a serum marker.
    Wald NJ; Densem JW; George L; Muttukrishna S; Knight PG
    Prenat Diagn; 1996 Feb; 16(2):143-53. PubMed ID: 8650125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study.
    Phillips OP; Elias S; Shulman LP; Andersen RN; Morgan CD; Simpson JL
    Obstet Gynecol; 1992 Sep; 80(3 Pt 1):353-8. PubMed ID: 1379701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.